Aerska
aerska.com
Actively hiring
Biotechnology
Health Care
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
News
Aerska Appoints Laura Sepp-Lorenzino to Scientific Advisory Board
Appointment supports Aerska
Read more
Report
Aerska Appoints Laura Sepp-Lorenzino to Scientific Advisory Board
Appointment supports Aerska
Read more
Report
Aerska Strengthens Board with Appointments of Uli Stilz and Itziar Canamasas
DUBLIN and LONDON, 15 June 2026 -- Aerska, a biotechnology company using brain shuttle technology to develop RNA medicines for CNS diseases, today announces the appointment of Itziar Canamasas and Uli Stilz to the Company's Board of Directors.
Read more
Report
Aerska Strengthens Board with Appointments of Uli Stilz and Itziar Canamasas
DUBLIN and LONDON, 15 June 2026 -- Aerska, a biotechnology company using brain shuttle technology to develop RNA medicines for CNS diseases, today...
Read more
Report
Aerska Strengthens Leadership and Board with Key Appointments to Advance Systemically Delivered RNA Medicines for the Brain
Stuart Milstein appointed Chief Platform Officer, bringing decades of experience in oligonucleotide drug development to underpin Aerska's platform...
Read more
Report
Aerska: $39 Million Series A Raised For Advancing Brain Shuttle RNA Medicines
Aerska, a biotechnology company developing brain shuttle technology to deliver RNA medicines to the central nervous system, has closed a $39 million Series A financing led by EQT Dementia Fund and age1, with participation from Iaso Ventures and continued
Read more
Report
Irish biotech Aerska raises $39m Series A to deliver RNA meds to the brain
Irish biotech Aerska aims to improve delivery of RNAi interference (RNAi) therapeutics across the blood-brain barrier for treating neurological diseases.
Read more
Report
EQT Life Sciences co-leads USD 39 million Series A in Aerska to help systematically deliver RNA medicines to the brain
Series A financing will be used to advance Aerska
Read more
Report
Aerska Raises $39M Series A Financing led by EQT Dementia Fund and age1 to Systemically Deliver RNA Medicines to the Brain
Brings total funds raised to $60 million since launch, months after its seed funding announcement in October 2025Appoints Arno de Wilde, Philip Scheltens and Alex Colville to its Board of Directors DUBLIN and LONDON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Aers
Read more
Report
Biotech doubles financing in quest to silence genes behind neurological diseases
Aerska Therapeutics, based in Dublin and London, is focused on using 'brain shuttles' to deliver molecules past blood-brain barrier.
Read more
Report
Show more news
Tech stack
Technologies named in job postings at Aerska over the last 12 months, by layer, with the share of postings for each.
Technologies in use
1
Postings analysed
1
Stack modernity
85/100
Languages
1C
Sign in to see how your skills match this stack
Sign In
Growth
Hiring Momentum
28/100
Slowing
Open positions
1
0 opened / 0 closed in 30 days
ATS activity
Every ~3 days
10/05/2026
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Science & Research
100% ▲
Financials
Total raised
$39M
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2026 | $39M | Details |